Información del artículo
Resumen
Presentamos un caso clínico de un paciente afecto de insuficiencia renal crónica secundaria a poliquistosis renal del adulto portador de un injerto renal de cadaver funcionante que tras la conversión de ciclosporina a sirolimus, presenta una lesión eritematosa, no pruriginosa, que cede tras la retirada del fármaco. Valoramos la farmacoterapia del sirolimus en el trasplante y realizamos una revisión bibliografica de la literatura médica.
Palabras clave:
Trasplante renal
Sirolimus
Efecto adverso
Laburpena
Polikistosiak eragindako giltzurrun-gutxiegitasun kronikoa duen gaixo baten kasua azalduk dugu, zeinari giltzurruneko transplantea egin zitzaion. Ziklosporinaren ordez sirolimus eman zitzaionean, hazkura gabeko eritema agertu zuen, farmakoa etentzean desagertu zena. Transplantean sirolimusen farmakoterapia baloratuko dugu, eta bibliografiaren araketa egingo dugu ondoren.
Hitz adierazgarriak:
iltzurrun-transplantea
Sirolimus
Erasana
Summary
We presented a clinical case of a patient affection of secondary chronic renal insufficiency to renal poliquistosis of the carrying adult of a renal graft of cadaver that after the cyclosporin conversion to sirolimus, displays sn erythematous injury, nonpruirginosa, that yilds after the retirement of the drug. We valued the farmacoterapia of sirolimus in the transplant and made a review medical literature.
Key words:
Kidney Transplant
Sirolimus
Adverses Effects
El Texto completo está disponible en PDF
Referencias bibliográficas
[1.]
Spiegel D.M..
Terapia de sustitución renal: diálisis y trasplante.
Manual of Nephrology, 5ª, pp. 168
[2.]
Pallardo L.M..
Complicaciones a largo plazo del trasplante renal.
Nefrología clínica, 2, pp. 909
[3.]
Brazelton T.R., Morris R.E..
Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus, sirolimus, mycophenolate mofetil and leflunomide.
Curr Opin Immunol, 8 (1996), pp. 710-720
[4.]
Hong J.C., Kahan B.D..
Use of anti-CD25 monoclonal antibody in combination with rapamicin to eliminate cyclosporine treatment during the induction phase of immunosuppresion.
Transplantation, 68 (1999), pp. 701-704
[5.]
Data on File, Wyeth-Ayerst Pharmaceuticals. A double-blind, comparative study of the effect of two dose levles of sirolimus versus azatioprine, administered concomitantly with standard immunosupressive therapy in renal allograft recipients: 6- month final report (protocol 0468E1-301-US) GMR-27593-1998.
[6.]
Data on File, Wyeth-Ayerst Pharmaceuticals. Ascending single dose safety, tolerance and pharmaokinetic, study of oral sirolimus solution in pediatric patients with stable chronic renal failure receiving hemodialysis or peritoneal dialysis: final report (protocol 0468E1-147-US). GMR-31333, 1998.
[7.]
Data on File, Wyeth-Ayerst Pharmaceuticals. Pharmacokinetics of sirolimus in patients with chronic hepatic impairment and in healthy adults: final report (protocol 0468E1-134-US). GMR-31333, 1998.
[8.]
Groth C.G., Backman L., Morales J.M., Calne R., Kreis H., Lang P., Tourane J.L., Claersson K., Campistol J.M., Durand D., Wramner L., Brattström, Charpenter B..
Sirolimus(Rapamycin) based therapy in human renaltransplantation.
Transplantation, 67 (1999), pp. 1036-1042
[9.]
Kreis H., Cisterne J.M., Land W., Wramner-Lang P., Tourane J.L., Claersson K., Campistol J.M., Durand D., Wramner L., Brattstróm, Charpenter B..
Sirolimus (Rapamycin) based therapy inhuman renal transplantation.
Transplantation, 67 (1999), pp. 1036-1042
[10.]
Kreis H., Cisterne J.M., Land W., Wramnerlang P., Wramner L., Squifflet J.P., Abramowicz D., Campistol J.M., Morales J.M., Grinyo J.M., Mourad G., Berthoux F.C., Brattstróm C., Lebranchu Y., Vialtel P..
Sirolimus(Rapamycin) in association with mycophenolatemofetil induction for the prevention of acutegraft rejection in renal allograft recipients.
Transplantation, 69 (2000), pp. 1252-1260
[11.]
Hong J.C., Kahan B.D..
A calcineurin antagonist-free induction immunosuppression strategy for delayed graft function.
in kidney transplantation. Transplantation Proceedings, 33 (2001), pp. 1271-1272
[12.]
Johnson R.W.G., Kreis H., Oberbauer R., Brattstróm C., Claersson K., Eris J..
Sirolimusallows early cyclosporine withdrawal in renaltransplantation resulting in improved renal function and lower blood pressure.
Transplantation, 72 (2001), pp. 777-786
[13.]
Weir M..
Impact of inmunosupprensive regimen on posttransplant diabetes mellitus.
Transplanatation Proceedings, 33 (2001), pp. 23S-26S
[14.]
Morelon E., Mamzer-Brunecl M.F., Peraldi M.N., Kreis H..
Sirolimus: a new promising immunosuppressive drug. Towards a rationale for itsuse in renal transplantation.
Nephrol Dial Transplant, 16 (2001), pp. 18-20
[15.]
MacDonald A.S., The Rapamune Global Study Group.
A worldwide, phase III, randomined, controlled, safety and efficacy study of asirolimus/cyclosporine regimen for preventionof acute rejection in recipients of primary mismatched renal allografts.
Transplantation, 72 (2001), pp. 271-280
[16.]
Kahan B.D..
Efficacy of sirolimus comparedwith azathioprine for reduction of acute renalallograft rejection: a randomised multicentrestudy. The Rapamune US Study Group.
Lancet, 356 (2000), pp. 194-202
[17.]
MacDonald A.S..
Management strategies for nephrotoxicity.
Transplantation, 69 (2000), pp. S831-S836
[18.]
Flechner S.M., Goldfare D., Modlin C., Feng J., Krishnamurth V., Mastroianni B., Savas Cook D.J., Novick A.C..
Kidney transplantation without calcineurin inhibitor drugs: Prospective randomizedtrial of sirolimus versus cyclosporine.
Transplantation, 74 (2002), pp. 1070-1076
[19.]
Hong J.C., Kahan B.D..
A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients atrisk for delayed graft function.
Transplantation, 72 (2002), pp. 1320-1328
[20.]
Guba M., Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., Jauch K.W., Geissler E.K..
Rpamycin inhibits primary and metastatictumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.
Nature Med, 8 (2002), pp. 128-135
[21.]
Smith K.D., Wrenshall L.E., Nicosia R.F., Pichler R., Marsh C.L., Alpers C.E., Polissar N., Davis C.L..
Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use.
J Am Soc Nephrol, 14 (2003), pp. 1037-1045
[22.]
Davis C..
Sirolimus delays renal allograft recovery.
Am J Transplant, 3 (2003), pp. 363-365
Copyright © 2004. Academia de Ciencias Médicas de Bilbao